Lancet Oncol
February 2017
Background: The evidence justifying the use of acellular dermal matrices (ADMs) in implant-based breast reconstruction (IBBR) is limited. We did a prospective randomised trial to compare the safety of IBBR with an ADM immediately after mastectomy with that of two-stage IBBR.
Methods: We did an open-label, randomised, controlled trial in eight hospitals in the Netherlands.